Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
81 Results for "
T-L
" in MedChemExpress (MCE) Product Catalog:
Products (81)
81 Results for "T-L" in MCE Product Catalog:
47
Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
19
19 Cited Publications
Synonyms: Salinosporamide A; NPI-0052
Target:
8
8 Cited Publications
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .
2
2 Cited Publications
TL13-112 is a ALK PROTAC degrader. TL13-112 degrades the NPM-ALK protein by recruiting the CRBN E3 ligase, thereby blocking oncogenic signal transduction such as STAT3, ERK and AKT, and relieving the transcriptional repression of CD45, CCR7 and PI3Kδ. TL13-112 can be used in related research on anaplastic large cell lymphoma .
2
2 Cited Publications
Cat. No.: HY-P7306
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFSF10; APO2L; TNF Superfamily Member 10; Tumor Necrosis Factor (Ligand) Family, Member 10; Apo-2L; Tumor Necrosis Factor Ligand Superfamily Member; TRAIL; TNF-Related Apoptosis Inducing Ligand TRAIL; CD253; Tumor Necrosis Factor Superfamily Member 10; TANCR; TNF-Related Apoptosis-Inducing Ligand; TL2; Tumor Necrosis Factor Ligand 6A; Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10; CD253 Antigen; Tumor Necrosis Factor (Ligand) Superfamily, Member 10; Protein TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; TNLG6A; Apo-2 Ligand
Species:
Human
Source:
E. coli
1
Target:
Research Areas:
Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/mL, TROP2 Kd of 0.3083 nM, and topoisomerase I IC50 of 0.7 μM. Sacituzumab tirumotecan is composed of the humanized anti-TROP2 antibody Sacituzumab (HY-P99045), the drug-linker conjugate for ADC is TL033 TFA (HY-147340A). Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .
1
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P990006
CAS No.: 2750005-84-4
Synonyms: TEV-48574; SAR-447189; TEV-574
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P990876
CAS No.: 2911580-96-4
Synonyms: PF-06480605 (WT IgG1); RVT-3101 (WT IgG1)
Target:
Research Areas:
Afimkibart (PF-06480605) (WT IgG1) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart (WT IgG1) is a monoclonal antibody that retains the native, wild-type IgG1 Fc structure without any engineered modifications; unlike Afimkibart (HY-P990876A), it does not contain the L234A, L235A, or G237A mutations. Afimkibart (WT IgG1) can be used for the research of inflammatory bowel disease .
1
1 Cited Publications
Cat. No.: HY-20457
CAS No.: 1268163-15-0
Research Areas:
TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
1
1 Cited Publications
TL12-186 is a multi-kinase PROTAC degrader. TL12-186 recruits the CRBN E3 ubiquitin ligase to target and degrade a variety of distinct kinases, including FLT3, BTK, AURKA, PTK2B, and multiple cyclin-dependent kinases (CDKs). TL12-186 can be used in leukemia-related research .
1
Target:
Research Areas:
Flixebrutinib (TL-895) is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. Flixebrutinib is active against recombinant BTK (average IC50: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC50 = 1.6 nM) and TXK with IC50 within tenfold of BTK activity. Flixebrutinib inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC50: 1-10 nM). The Flixebrutinib effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. Flixebrutinib is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies .
1
1 Cited Publications
Cat. No.: HY-P701048
Purity: ≥ 95%, as determined by reducing SDS-PAGE or Bis-Tris PAGE.
Synonyms: TNFSF15; TL1A; TNF Superfamily Member 15; Vascular Endothelial Growth Inhibitor-192A; Vascular Endothelial Cell Growth Inhibitor; Vascular Endothelial Growth Inhibitor; TNF Ligand-Related Molecule 1; TNF Superfamily Ligand TL1A; VEGI; MGC129934; TL1; MGC1
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P7319
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TNFSF18; Activation-Inducible TNF-Related Ligand; TNF Superfamily Member 18; GITRL; HGITRL; Glucocorticoid-Induced TNFR-Related Protein Ligand; AITRL; Tumor Necrosis Factor Superfamily Member 18; TL6; Tumor Necrosis Factor Ligand 2A; Tumor Necrosis Factor
Species:
Mouse
Source:
E. coli
Cat. No.: HY-147340
CAS No.: 2356230-22-1
Synonyms: Tirumotecan
Target:
Research Areas:
TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
Cat. No.: HY-147340A
CAS No.: 2746343-70-2
Synonyms: Tirumotecan TFA
Target:
Research Areas:
TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
Cat. No.: HY-P990151
Target:
Research Areas:
Cat. No.: HY-P991440
Target:
Research Areas:
Research Areas:
TL13-12 is a CRBN-recruiting ALK PROTAC degrader, with a DC50 of 10 nM in H3122 cells. TL13-12 induces dimerization of CRBN and truncated ALK, which brings the DNA-binding domain and transactivation domain into close proximity, thereby activating the expression of downstream reporter genes, while exhibiting extremely low leaky expression under non-inducing conditions. TL13-12 serves as a tool molecule for the orthogonal PROTAC-CID system, and is applied in research on non-small cell lung cancer, anaplastic large cell lymphoma, and neuroblastoma .
Cat. No.: HY-169396
CAS No.: 2769753-10-6
Synonyms: TL13-87
Target:
Ligands for Target Protein for PROTAC Microtubule/Tubulin YTHDF CDK Btk FLT3 Aurora Kinase Tyrosinase ULK Itk
Research Areas:
TAE648 is a target protein ligand of PROTAC SK-3-91 (HY-137341) (Ligand for Target Protein for PROTAC). TAE648 can be used for synthesis PROTAC . TAE648 decreases monolayer-cultured SKOV3ip1 cell viability .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
